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Abstract
Background: This 7 year NIHR programme [2011–2018] tests the primary hypothesis that the NDPS diet and
physical activity intervention will reduce the risk of transition to type 2 diabetes (T2DM) in groups at high
risk of Type 2 diabetes. The NDPS programme recognizes the need to reduce intervention costs through
group delivery and the use of lay mentors with T2DM, the realities of normal primary care, and the
complexity of the current glycaemic categorisation of T2DM risk.
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Methods: NDPS identifies people at highest risk of T2DMon thedatabases of 135general practices in the East of England for
further screeningwith ab fastingplasmaglucose andglycosylatedhaemoglobin [HbA1c]. Thosewith an elevated fasting
plasmaglucose [impaired fasting glucose or IFG]with orwithout an elevatedHbA1c [non -diabetic hyperglycaemia; NDH] are
randomised into three treatment arms: a control arm receivingno trial intervention, an arm receiving an intensive bespoke
group-baseddiet andphysical activity intervention, and an arm receiving the same interventionwith enhanced support from
peoplewith T2DM trained as diabetes preventionmentors [DPM]. Theprimary endpoint is cumulative transition rates to
T2DMbetween the two interventiongroups, andbetween each interventiongroup and the control group at 46months.
Participantswith screendetected T2DMare randomized into an equivalent prospective controlled trial with the same
intervention and control armswith glycaemic control [HbA1c] at 46months as theprimary endpoint. ParticipantswithNDH
and a normal fasting plasmaglucose are randomised into an equivalent prospective controlled intervention trial with follow
up for 40months. The intervention comprises six education sessions for the first 12weeks and thenup to 15maintenance
sessions until intervention end, all delivered in groups, with additional support fromaDPM inone treatment arm.
Discussion: TheNDPSprogramme reports in 2018 andwill provide trial outcomedata for a groupdelivereddiabetes
prevention intervention, supportedby laymentorswith T2DM,with intervention inmultiple at risk glycaemic categories, and
that takes into account the realities of normal clinical practice.
Trial registration: ISRCTN34805606 (Retrospectively registered 16.3.16)
Keywords: Type 2diabetes, Diabetes prevention, Impaired fastingglucose, Nondiabetic hyperglycaemia, Laymentors,
Lifestyle intervention
Background and rationale
The number of people with T2DM worldwide quadru-
pled between 1980 and 2014, from 108 to 422 million
[1] with international ambition aimed at holding the age
standardised T2DM prevalence at 2010 levels [2]. Land-
mark clinical trials suggest that intensive lifestyle (diet
and physical activity) intervention in a research setting
reduces the risk of T2DM in highest risk groups [3–5].
These clinical prevention trials have largely focused on
intensive lifestyle interventions in people at highest risk,
usually with a plasma glucose (fasting or during an oral
glucose tolerance test) or glycosylated haemoglobin
(HbA1c), that is elevated, but not to any diagnostic
threshold for diabetes [3–5]. In these trials the effect size
is consistent [4, 5], and there may be long term benefi-
cial legacy effects of the trial intervention, even after the
intervention is withdrawn. Despite this, there remain
concerns about the translatability of this trial evidence
into normal clinical practice at scale, partly because of
the very high costs associated with individualized inter-
vention, and smaller effect sizes in ‘real world’ interven-
tions [6–8]. These concerns were valid when the NDPS
programme commenced in 2011 and remain valid now,
despite the launch of the NHS England diabetes preven-
tion programme [9]. The costs of diabetes prevention
intervention can be reduced by group based delivery [6]
and the team who delivered the landmark study in this
area recognised that ‘community health workers’ could
be an attractive model for delivering lifestyle interven-
tion at reduced cost [6]. There has been growing interest
in this model over the last few years for the clinical
management of Type 2 diabetes, and to a lesser degree
in diabetes prevention [10–12]. Recent changes in the
diagnostic criteria for diabetes, with a shift from glucose
based criteria to one based on HbA1c, with a diagnostic
threshold of an HbA1c ≥48 mmol/mol is widely sup-
ported and adopted [13, 14]. However, this policy gener-
ates a large new population with prediabetes, usually
defined as HbA1c ≥42–<48 mmol/mol. NICE PH38 pol-
icy guidance [15] is that these patients should receive
intensive lifestyle advice and annual HbA1c monitoring,
but there is relatively little trial evidence that this leads
to a reduced T2DM incidence in this population [6–8].
There is still an active debate about the best approach to
find those at highest risk of developing T2DM, and
which glycaemic category should receive a clinical or
research diabetes prevention intervention [6]. Glucose
tolerance tests (GTT) are time consuming, unsuitable
for mass population screening in ordinary primary care,
and are unpopular with patients clinically and in clinical
trials [16, 17]. Identifying those at highest T2DM risk for
a trial intervention that translatable into normal clinical
practice, must reflect the usual approach in normal clin-
ical practice, which for some time has been based on
HbA1c and fasting plasma glucose data. However, most
of the large trials have examined populations defined as
at risk using a GTT [6–8]. One final issue is that case
finding for those at highest risk for entry to prevention
trials or clinical prevention programs using widely avail-
able risk prediction algorithms may not be easily applic-
able in all primary care as some of the key variables in
these risk prediction tools may be unavailable [18]. Mass
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screening in primary care for high risk individuals
should reflect existing primary care models and available
data, with limited additional workload.
Need for trial
The aim of this 7 year NIHR funded programme
[PGfAR RP – PG - 0109-10013] is to test the primary
hypothesis that our novel diet and physical activity
intervention reduces the risk of T2DM in a screened
target population of UK adults with high risk of pro-
gression to type 2 diabetes (T2DM). The programme
comprises a large screening and risk identification
study, and a suite of randomised controlled trials de-
signed to assess the effectiveness of a realistic diabetes
prevention intervention, that is community based, with
recruitment through general practice. The trials are
based in the realities of current NHS care, with inter-
ventions delivered in groups in the local community, in
part by lay mentors with T2DM, with minimal impact
on general practice. The programme recognises the
current complexity of screening and glycaemic categor-
isation of patients at risk of diabetes, including screen
detected T2DM.
Specific objectives and hypotheses
The NDPS programme has several elements: a screening
programme [Project 1] to identify those at highest risk
of T2DM on general practice databases in the East of
England. The main element of the programme is then a
randomised controlled prospective three - arm trial in
those participants found to be at highest risk [Project 2],
with one intervention arm supported by lay mentors
[Diabetes Prevention Mentors; DPM] who have T2DM
themselves. Project 3 is the recruitment, training and
retention of these DPM. Project 4 ia a randomised con-
trolled prospective three - arm trial of the same inter-
vention[s] in people found to have a new diagnosis of
screen detected T2DM in Project 1. Project 5 is the
health economic analysis of these projects. Finally, Pro-
ject 6 is a randomised controlled prospective two -arm
pilot intervention in participants found in Project 1
screening to have non - diabetic hyperglycaemia (NDH)
but with a normal fasting glucose in Project 1.
Project 1 objective
To screen 10,000 participants at high risk of T2DM
for non-diabetic hyperglycaemia [NDH; HbA1c ≥42
to <48 mmol/mol] or impaired fasting glucose [IFG; ≥ 5.6
to <7.0 mmol/l] to identify participants for randomisation
into one of a suite of randomised clinical trials.
Project 2 hypothesis
The cumulative incidence of T2DM will be signifi-
cantly lower after 46 months in a high risk group
with impaired fasting glucose [IFG; fasting plasma
glucose ≥6.1 to <7.0 mmol/l] or with non -diabetic
hyperglycaemia [NDH; HbA1c ≥42 to <48 mmol/mol]
and an elevated fasting plasma glucose [≥5.6 to <6.1 mmol/l]
randomised to our lifestyle intervention [standard interven-
tion group], compared to a group randomised to this inter-
vention enhanced by additional lay diabetes prevention
mentor [DPM] input, or to a control group who do not
receive any trial intervention.
Project 3 hypothesis
We can identify, recruit, train and retain 70 volunteers
with known T2DM to become diabetes prevention men-
tors [DPM] to support one intervention arm in each of
Projects 2 and 4.
Project 4 hypothesis
Mean HbA1c [as a measure of glycaemic control] will be
significantly lower after 46 months intervention in par-
ticipant groups with newly diagnosed screen detected
T2DM [fasting plasma glucose >7.0 mmol/l and/or
HbA1c >48 mmol/mol] randomised to the same inter-
vention groups as in Project 2 than in an equivalent con-
trol group who do not receive this trial intervention.
Project 5 objective
Health economic analysis of all aspects of the programme.
Project 6 objective
To observe changes in mean HbA1c after 40 months in
participants with non - diabetic hyperglycaemia [NDH;
HbA1c ≥42 to <48 mmol/mol] and a normal fasting
plasma glucose [<5.6 mmol/l] randomised to an observa-
tional controlled trial of our standard intervention com-
pared to a control group not receiving this intervention.
Allocation into trial by glycaemic category is sum-
marized in Table 1
Methods and design: Description of intervention
trials design
Project 2 is a unblinded three - arm randomised parallel
group 46 month clinical trial with randomisation of the
target population at risk of T2DM (Table 1) to either a
control group who do not receive the research interven-
tion, or an intervention group who receive the 46 month
diet and lifestyle intervention described below, or an inter-
vention group who recieve the 46 month lifestyle interven-
tion enhanced with additional direct contact from DPM.
Project 3 is a recruitment project for DPMs to service
one intervention arm of Project 2. The DPM aid in the
delivery of the intervention, but are themselves studied
with additional observational baseline and prospective
clinical and biochemical assessments at prespecified time
points during their involvement.
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Project 4 is a three - arm randomised parallel group
46 month prospective clinical trial with randomisation
of the target population with screen detected T2DM
(Table 1) to either a control group who do not receive
the research intervention, or an intervention group who
receive the 46 month diet and lifestyle intervention
described below, or an intervention group who recieve
the 46 month lifestyle intervention enhanced with add-
itional direct contact from trained volunteers with
T2DM [DPM].
Project 6 is two arm randomised parallel group
40 month prospective pilot clinical trial with randomisa-
tion of the target population (Table 1) to either a control
group who do not receive the research intervention, or
an intervention group who receive the standard diet and
lifestyle intervention described below.
Randomisation and allocation
Project 2 and 4 are powered to detect the primary out-
come at end point (see below), but Project 6 is a pilot
controlled trial intended to inform the design of future
intervention trials as little evidence exists currently to
allow power estimates in this glycaemic category. Ran-
domisation of participants is conducted automatically
using a dedicated function in the trial data management
system. The randomisation mechanism for Project 2
consists of a pre-prepared random list of codes [for the
Intervention and control groups] that are stored in the
trial database. To reduce the risk of predicting the next
allocation while maintaining a reasonable even spread of
intervention and control patients, the list is constructed
of blocks of 17 codes [3 Control, 7 intervention and 7
Intervention + DPM]] to approximate the proportions of
170:390:390 respectively. The list was built prior to the
start of the programme using standard Microsoft tools.
Randomisation is asymmetric to deliver the sample sizes
described. Project 4 and the Project 6 pilot Project are
randomised using the same method in the trial data
mangement system. Project 4 are randomised to a 1:1:1
ratio and the Pilot Project is randomised to a 1:1 ratio to
control or standard intervention only.
Methods: participants, interventions and
outcomes
Study setting and infrastructure
The programme is hosted by the Norfolk and Norwich
University Hospital NHS Trust, Norwich UK, and
NDPS programme staff work from the Norwich Clinical
Research and Trials Unit [CRTU] at the University of
East Anglia [UEA] Norwich. The programme is sup-
ported by the Clinical Trials Unit (CTU), Norwich. The
programme works with 135 general practices in the
East of England [Norfolk, Suffolk and North East Essex]
to screen and recruit into Project 1, and the
programme screens and delivers the interevention at 8
sites in existing NHS and University facilities, across
the East of England.
Participant eligibility criteria: primary care relationships
and contact (Tables 2 and 3)
The population of Norfolk in 2011 was 891,100 with a
projected population of 935,800 by 2018 and 60% are
more than 40 years old, with 5.7–9.4 per cent of the
total from an ethnic minority group depending on the
chosen definition. Current data suggest that the tar-
geted Norfolk population is approximately 550,000
aged ≥40–≤75, registered at 137 GP practices within
five Clinical Commissioning Groups [CCG’s] through-
out Norfolk. The targeted central Ipswich (Suffolk)
population has a registered population of 125,374 pa-
tients aged ≥40–≤75 in 32 GP practices in one CCG
and the targeted North East Essex area [largely central
Colchester] has an estimated population of 171,545
patients aged ≥40–≤75 in 38 GP practices in one tar-
geted CCG. NDPS have contacted 207 GP practices
within these seven CCG’s, providing the programme
with a total population of 846,919 potentially eligible
participants. All GP practices are invited to particpate
and the GP practice’s electronic health record [EHR]
software such as SystmOne and EMIS [The Phoenix Part-
nership TPP, TPP House Horsforth Leeds, UK and EMIS
Health Rawdon House, Yeadon, Leeds, UK] is interrogated
for patients eligible for Project 1. EHRs are real-time,
patient-centred records that make information available
Table 1 Glycaemic category [based on concordant paired baseline results] in project 1 and associated randomisation into trial
Diagnosis Confirmed diagnosis based on concordant paired results Randomised to Project
Normal result Fasting plasma glucose <5.6 mmol/l and HbA1c <42 mmol/mol. No Trial
Impaired fasting glucose [IFG] Fasting plasma glucose ≥6.1–<7.0 mmol/l and HbA1c <48 mmol/mol Project 2
Non diabetic hyperglycaemia [NDH] HbA1c ≥42–<48 mmol/mol and fasting plasma glucose ≥5.6 to <6.1 mmol/l. Project 2
Impaired glucose tolerance [IGT] Fasting plasma glucose <7.0 mmol/l and a 2 h OGTT result of ≥7.8 and <11.1 mmol/l Project 2a
Type 2 diabetes [T2DM] HbA1c ≥48 mmol/mol and/or fasting plasma glucose ≥7.0 mmol/l Project 4
Non diabetic hyperglycaemia [NDH] HbA1c ≥42 to <48 mmol/mol and fasting plasma glucose <5.6 mmol/l . Project 6
aIGT: participants with IFG (≥6.1–<7.0 mmol/l) and NDH (≥6.1–<7.0 mmol/l) were invited to undertake an OGTT between 2011 and 2013 for diagnostic reasons to
exclude T2DM based on OGTT criteria before UK adoption of HbA1c diagnostic criteria for T2DM [15, 16], but not as a randomisation category
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instantly and securely to authorised users and make exten-
sive use of Read codes and digital information is search-
able via these codes. The GP practice is provided with the
coding criteria based on the study inclusion/exclusion cri-
teria (Tables 2 and 3). Patients are then written to directly
from the practice using Docmail, which allows mass mail-
ing by uploading and merging the generated patient list
with the NDPS mail pack documents. The system allows
the practice to securely upload the NDPS document tem-
plate and mail to patients via a secure web portal. The use
of Docmail for such purposes is permissible under guid-
ance from both the Information Commissioner’s Office
[ICO] and the Department of Health [DoH] UK, subject
to the provisions of the UK Data Protection Act 1998.
The NDPS mail pack consist of a patient invite letter and
the study Participant Information Sheet [PIS]. Docmail
Table 2 Inclusion and exclusion Criteria for Project 1 screening and all intervention projects
Inclusion criteria Exclusion criteria
Age 40 years or over and at least one of the below
risk factors:
Body mass index (BMI) ≥30 kg/m2
Parent, sibling or child with T2DM
Personal history of coronary disease
Previous history of gestational diabetes
OR
Known impaired fasting glucose, impaired glucose
tolerance and/or HbA1c NDH range
Not able to provide GP details i.e. not registered with a GP or unwilling for their GP to be contacted
Unable to give informed consent due to lack of capacity through severe mental health, learning
difficulties or significant cognitive impairment
Self-reported conditions which could adversely affect the trial results or patient clinical
wellbeing such as:
i. Terminal illness.
ii. Antipsychotic medication, which may affect glucose tolerance
iii. High dose oral steroids [>4 weeks or >7.5 mg]
iv. Active treatment for malignancy
v. Stage IV renal impairment or ongoing renal dialysis
vi. Pregnant or lactating
vii. Stage IV NYHA cardiac failure
Taking part in any research study which involves a dietary or lifestyle change intervention
[exceptions are participants in observational research studies] Participation in other research
studies are assessed on an individual basis
Inability to attend or comply with the interventions or follow-up scheduling
Living with or related to someone in the programme team
Diabetes Prevention Mentors inclusion criteria
Age 18 years or over
Diagnosed with T2DM for ≥2 years
GP/clinician advice on health grounds that participant should not take part or be contacted
Not able to provide GP details, not registered with a GP or unwilling for their GP to be contacted
Unable to give informed consent due to lack of capacity through severe mental health, learning
difficulties or significant cognitive impairment
Self-reported conditions such as:
i. Terminal illness.
ii. Active treatment for malignancy
iii. Stage IV renal impairment or ongoing renal dialysis
iv. Pregnant or lactating
v. Stage IV NYHA cardiac failure
Table 3 Coding criteria for General practice Electronic Health Record [EHR] database searches
Search criteria Coded criteria for EHR
Search 1 Age ≥50 years and ≤80 years and a BMI ≥30 kg/m2
ORa
Age ≥50 years and ≤80 years and a weight [men] ≥93 kg & weight [women] ≥78 kg [if no height recorded]
Search 2 Age ≥50 years and ≤80 years and a BMI of ≥25 kg/m2 with at least one or more of the following:
Parent, sibling or child with T2DM
Personal history of coronary disease
Previous history of gestational diabetes
Known history of non-diabetes hyperglycaemia
ORa
Age ≥50 years and ≤80 years and a weight [men] ≥77 kg & weight [women] ≥65 kg with least one
or more of the following:
Parent, sibling or child with T2DM
Personal history of coronary disease
Previous history of gestational diabetes
Known history of non-diabetes hyperglycaemia
Search 3 Age ≥40 years with one of the following
Known impaired fasting glucose [IFG] or impaired glucose tolerance [IGT]
Fasting glucose range of ≥6.1–≤6.9 mmol/l
Search 4 Age ≥40 years with one of the following
Fasting glucose range of ≥5.6–≤6.0 mmol/l inclusive
HbA1c range of ≥42–47 mmol/mol inclusive
aIn the case of no BMI record, these body weights (kg) would give a BMI > 25kg/m2 or > 30kg/m2 based on an assumed UK national average height (m)
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processes the mailing requirements via their website soft-
ware and is delivered by CFH Docmail LTD [CFH Practice
Index Ltd, London, UK. http://www.docmail.co.uk. Com-
pany Reg. No. 09018867]. In accordance with ‘best prac-
tice’ security features to protect patient data and in
compliance with the UK Data Protection Act 1998, no
data are released to the NDPS team. Following this mail
out interested patients contact the study team by phone
and a programme administrator checks study eligibility
with the potential participant via a detailed telephone
screening interview prior to booking the screening appoint-
ment (Table 4) Recruitment through GP database interro-
gation accounts for 90.7% of programme recruitment. Self
and direct GP referrals can be made via the NDPS website
(http://www.norfolkdiabetespreventionstudy.nhs.uk) or via
a central study telephone line.
Recruitment of Diabetes Prevention Mentors [DPM]
A central and novel part of this programme is the re-
cruitment of people with established T2DM on GP
registers who provide peer support by acting as life-
style mentors to the participants in the intervention
plus DPM arm of the programme. The DPM work with
Diabetes Prevention Facilitators [DPF] to deliver the
enhanced intervention. Each participant receives a
15 min semi-structured telephone call from the
DPM every 4 weeks during the education session
phase [first 12 weeks of programme] and then every
8 weeks between maintenance sessions. Before the
newly recruited DPM’s are offered their role they are
formally interviewed by the Senior Intervention
Research Associate and the Programme Manager/
Principal Investigator, with possible assistance from
a Diabetes Patient Champion [a lay person with diabetes
who represents the diabetes community]. DPM’s are
recruited following a successful Disclosure & Barring
Service [DBS] check and two satisfactory references. If
successful the DPM is given an NHS honorary volunteer
contract and receives specific training for their role. DPM
are recruited via GP database recruitment searches using
coding criteria (Table 3). Once a participant is randomized
into a DPM intervention group, their availability for
receiving calls is reviewed (NM) and assigned a DPM
based on the DPM availability to make calls. This allows
for the greatest possible call connnection rate.
Training of Diabetes Prevention Mentors (DPM)
The NDPS specific standardised training programme for
DPM (Table 5) is delivered in seven 120–150 min ses-
sions over a minimum of 4 weeks to allow time for
self-reflection and reading between each session. The
training has two clear aims 1] to provide up to date
information on physical activity, diet, pre diabetes.and
the impact of lifestyle on the the progression to T2DM
and 2] to practice (using role play) the key skills re-
quired. To successfully complete the group training
seminars and be cleared to work with study partici-
pants, DPMs are required to attend at least six of the
seven sessions (with sessions 3, 4, 5, 6, and 7 requiring
compulsory attendance). Furthermore, DPMs needed
to demonstrate an understanding of the intervention
theory and to demonstrate successfully the active lis-
tening skills required. During the seminars, the senior
research associate (NM) assesses the strengths and
learning needs of each trainee and structures their
following one to one practice training accordingly. The
one to one practice work consisted of telephone call/s
where DPMs adopt the role of the Mentor and the Senior
Research Associate adopts the role of a trial participant.
These calls model particular situations where it is felt the
DPM needs to be ‘tested’.
Baseline screening assessment for eligibility
(Table 6)
Following written informed consent, the screening
assessment records the following information to the se-
cure electronic trial database [eCRF] and on the Case
Report Form [CRF].
Outcomes and participant timeline
Tables 6, 7 and 8 and Fig. 1 outline the schedule of regis-
tration, screening assessments, interventions, and time
point assessments. In the event of a raised fasting plasma
glucose [>5.6 mmol/l] and/or HbA1c [≥42 mmol/l] in
Project 1, the participant is invited back for repeat testing
for fasting plasma glcuose and HbA1c. Classification of
glycaemic categories and eligibility for randomisation is
Table 4 Registration details on initial contact prior to screening
Date of birth
Gender
Height
Weight
Calculated BMI
Known first degree relative with T2DM
Known personal history of coronary disease
Known history gestational diabetes
Known previous result of IFG or IGT, prediabetes or Non-Diabetic
Hyperglycaemia
GP surgery address
Participant’s address
Recruitment route
Screening and intervention preferred site
Medication
Medical history
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made on the basis of concordant paired baseline mea-
surements, and sampling is repeated if necessary until
paired concordant data allow classification. Samples for
fasting lipids and insulin are also taken at this second
appointment to form the baseline trial results. The lifestyle
intervention comprises of 6 × 2 h education sessions of
varying content for the first 12 weeks of the intervention
which provide information and encourage decision mak-
ing about behaviour change, increase motivation to
change support lifestyle changes in relation to physical ac-
tivity and diet with individual goal setting, action planning
and self-monitoring. This core programme is followed by
up to 15 maintenance sessions held 8 weeks apart from
month 4 until intervention end which include facilitated
discussion and physical activity circuits. Participants at-
tend group based sessions, led by a trained DPF. On aver-
age there are eight participants in each group, with a
maximum of 12. The groups remain together for the dur-
ation of the study, providing motivation for one another
and a supportive network as the group bonds. All partici-
pants in the trial arms are expected to attend a 34 month
active intervention, comprising of the 3 months education
sessions, one month break post education and 30 months
of maintenance sessions. All participants, including partic-
ipants in the control arm, are required to attend clinic
time point appointments at 6, 12, 24, 36, 40 and 46 month.
Assessment includes recording to the secure electronic
trial database and the time point CRF.
NDPS intervention (Additional files 1 and 2)
Participants with a randomisable category (Table 1)
attend group based sessions, and intervention arms are
not mixed in session attendance. Facilitators focus on
group dynamics and the inclusion of all participants in
discussions is encouraged. Maintenance sessions begin
by reviewing behaviour change progress, followed by en-
gagement in a physical activity circuit. An interactive
topical discussion is included to aid continued learning
and development and increase motivation. Each session
Table 5 Summary of diabetes prevention mentor (DPM) training seminars content and aims
Training setting Seminar number Seminar title Session
length
PowerPoint
presentation
Practice
work
Practice work aims
Group One Introduction and
Getting Started
2 h Yes No n/a
Group Two Healthy Eating and
Fats
2 h Yes No n/a
Group Three Active Listening Skills 2.5 h No Yes First practice of Active Listening Skills
Group Four Getting Active 2 h Yes Yes Practice Opening and Closing of a call
Group Five Portion Control and
Labels
2 h Yes Yes Practice Active Listening Skills in content
of call conversation
Group Six Motivational
Interviewing
2.5 h No Yes First practice call (duration 15 min), introduction
of Motivational Interviewing skill set
Group Seven Maintaining
Change
2 h Yes Yes Full practice call (duration 20 min)
One to One 1st practice Call n/a 20 mins. n/a Yes Assessment application of taught skill set
One to One Additional practice calls n/a 20 mins n/a Yes Additional assessment if required
Table 6 Screening assessment
NDPS screening assessment - appointment 1
Ethnicity
Smoking status
Waist circumference [cm]
Height [cm]
Weight [kg]
Body mass index [BMI kg/m2]a
Body fat mass [kg]a
Visceral fat [kg]a
Body fat percentagea
Known first degree relative with T2DM
Known personal History of CHD
Known Gestational diabetes
Known previous result of IFG or IGT, prediabetes or Non-Diabetes
Hyperglycaemia
GP surgery address
Participant’s address
Recruitment route
Screening and intervention preferred site
Have they been contacted about the national diabetes prevention
programme or equivalent:define
Has the participant been admitted to hospital since their last visit, which
has not already been reported and recorded for Serious Adverse Events
and Adverse Events [SAE & AE] purposes
ameasuredusingaTanitabody fat Bio-impedance compositionanalyser. The Tanita
provides anelectronicmeasurement of thebody’s composition [tissueand fluid].
[TANITA -Hoogoorddreef, 1101BE,Amsterdam, TheNetherlands.Model BC-420MA]
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is concluded by the inclusion of goal setting activity in-
cluding action and coping planning, links are made from
the solutions, and barriers discussed during the progress
review to aid the setting of new goals. There is a sub-
stantial programme infrastructure for process analysis,
intervention fidelity and participant adherence, and the
intervention was developed in line with the MRC frame-
work for the development and evaluation of Randomised
Controlled Trials for complex health interventions [19].
This involved the following stages: 1) Extensive stake-
holder involvement and needs assessment (interviews and
discussions with service users [20] and potential service
providers as well as with experts in the fields of diabetes,
diabetes prevention, behaviour change and intervention
delivery) 2). Reviewing of existing literature [3, 21–23] 3)
Development (by the NDPS intervention development
working group of an underpinning theoretical model de-
scribing the processes of behaviour change targeted by the
intervention (Fig. 1) 4) Selection, based on evidence
(where available) and expert opinion, of intervention strat-
egies to deliver each of the intervention processes defined
by the logic model.
Underpinning theory
Following consideration of several alternatives, the the-
ory selected for developing the Intervention was the
Process Model of Lifestyle Behaviour Change [24, 25].
This theoretical model was adapted from the Health Ac-
tion Process Approach, [26, 27] and includes modifica-
tions to place a greater emphasis on self-monitoring,
social support, use of coping plans and relapse manage-
ment. The key intervention processes are i) increasing
motivation (perceived importance of healthy lifestyle,
self-efficacy for achieving healthy lifestyle, perceived risk
and outcome expectations); ii) making a specific action
plan (including plans for social support and for overcom-
ing barriers (coping plans)) and iii) supporting mainten-
ance through repeated ‘self-regulatory cycles’ of planning,
self-monitoring and other feedback (for example on blood
sugar), problem-solving to manage setbacks and revision
of action plans. There is also an emphasis on empowering
participants to develop autonomous motivation and to
“make changes you can live with” to ensure that plans for
lifestyle change are sustainable.
Structure
The NDPS Lifestyle Intervention begins with six 2-h
group based education/behaviour change intervention
sessions spread over 12 weeks, After a 4 week gap,
this is followed by up to 15 2.5-h group based main-
tenance sessions (including behaviour maintenance
techniques and 50 min of structured exercise) deliv-
ered every 8 weeks (see Fig. 2 for session timings).
The ingroup size is initially 10–12 participants, with
Table 7 Schematic diagram schedule of registration, screening assessments, interventions, and time point assessments for Project 2,
4 and 6a for intervention and control groups
Screening Randomisation Post-randomisation Exit
1st 2nd
Timepoint [months] 4 6 12 24 36 40 46
Registration x
Eligibility screen x x x
Informed consent x x
Fasting plasma glucose x x x x x x x x
HbA1c x x x x x x x x
Fasting lipid profile x x x x x x x
Fasting plasma insulin x x x x x x x
HOMA IR x x x x x x x
Blood pressure x x x x x x x
Height x
Weight x x x x x x x x x
BMI x x x x x x x x x
Waist circumference x x x x x x x x x
Body fat mass x x x x x x x x x
Body fat % x x x x x x x x x
Accelerometerb x x x x x x x x
aParticipants consented to Project 6 do not receive lipid and insulin analysis at baseline or at time points. These participants receive HbA1c and fasting plasma
analysis at the 6, 12, 24 and 40 time points only
bActigraph, LLC 17N, Tarragona Street, Pensacola, FL 32502, USA
Pascale et al. BMC Public Health  (2017) 17:31 Page 8 of 21
options to merge groups over time (at the mainten-
ance stage) if attendance diminishes. The total con-
tact time (assuming all maintenance sessions are
attended) is therefore 49.5 h, including 12.5 h of
structured physical activity.
Content
A detailed description of the intervention is provided
in Additional files 1 and 2. Briefly, the intervention
aims to reduce diabetes progression through increased
physical activity, specific changes in diet and weight
Table 8 Schematic diagram schedule of questionnaire assessments by time point for Projects 2,4 and 6
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Fig. 1 Schematic diagram schedule of registration, screening assessments, interventions, and time point assessments for Project 2 and 4
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loss. Behaviour change goals were set by participants
but the NDPS intervention encouraged participants to
shape these goals around 4 set targets; 1) If a BMI is
over 30 kg/m2 then to work towards a 7% weight loss
in the first 6 months and maintain until study end, 2)
Reduce the amount of fat and specifically saturated
fat from diet, 3) Work up to 150 min of moderate in-
tensity physical activity on 5 days of the week or
more which can be achieved through an increased
step count and 4) work up to increasing muscle
strength activity to 160–300 reps on 2–3 days of the
week as these are known to induce clinically mean-
ingful changes in diabetes risk for people with hyper-
glycaemia [3, 4].
Behaviour change techniques are selected to facilitate
each of the processes identified in the behaviour change
model and delivery strategies and detailed materials are
specified for each change technique. The programme
delivers these strategies and techniques in a logical se-
quence (Fig. 2; Additional file 1). This includes a focus on
one type of behaviour (diet or physical activity) in each of
the first six sessions and a combined focus in the mainten-
ance sessions. In the first six sessions, activities to imple-
ment behaviour change techniques are combined with
activities to build understanding around what lifestyle
changes to make (e.g. what is a healthy diet?, what is
moderate intensity activity?) and how to change them
(e.g., how to make a SMART-ER action plans, how to
identify and solve problems). Maintenance sessions then
focus on reviewing progress, problem-solving any setbacks
and reviewing action plans, as well as delivering a 50-min
session of supervised, structured physical activity. In terms
of specific strategies for lifestyle change, we present
national guidance on healthy eating (based on the EatWell
Guide [28] and compared existing diet to these recom-
mendations. However, participants were free to decide
what specific changes to make. We encourag participants
to choose physical activity that they can build into their
existing lifestyles and present ideas for muscle-
strengthening exercises. Structured activity is presented in
the maintenance sessions as a) as an opportunity to prac-
tice techniques in a safe, supervised environment, and b)
to reinforce the perception the programme is serious
about encouraging physical activity as well as dietary
change, as people may tend to focus more on the dietary
aspect of such programmes [29] To promote sustainability
of lifestyle change, we advise participants to make a series
of small, achievable changes, rather than dramatic
changes. We encourage participants to prioritise ideas for
change that would not detract from their enjoyment of
food (for dietary changes) or that would be enjoyable or
easy to build into a routine (for physical activity [30]).
Delivery and facilitator training
The initial six session “core” intervention is delivered to
each group of participants by a single facilitator (DPF)
where possible. The sessions are semi-structured with a
printed session plan and a set of Powerpoint slides for
each session. Presentation of the session is based on the
slides, with a mixture of didactic presentation (providing
information) and interactive activities (slides are paused
and participants engage in a discussion or other inter-
active activity, such as problem-solving, or action-
planning). Content is tailored to build on the existing
knowledge and skills of participants. The DPF spends
time with each individual who needs help during action-
planning activities and tries where possible (within the
limits of group-based delivery) to elicit and respond to
individual motivations, barriers to change or other con-
cerns. Flipcharts are used to keep track of ideas from the
group in a number of interactive activities and additional
printed information materials (handouts) are available
for a number of sessions covering a range of topics (for
example, healthy eating, why weight loss plateaus and
Fig. 2 The Process Model of Lifestyle Behaviour Change [24]
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what to do about it, a pictorial diagram of a set of
muscle-strengthening exercises that can be performed at
home/without any equipment),.
NDPS diabetes prevention facilitators (DPF) are re-
cruited from varied backgrounds and experience, including
academic qualifications in nutrition or physical activity, fit-
ness industry, and physiotherapy. A 5 day training course
was developed and delivered (primarily NM and CG). The
course content focuses on developing behaviour change
skills (Additional file 2), updating knowledge (for example
on healthy eating), using the intervention materials, deliv-
ering the session content using the slides and session plans
and data collection issues (including providing data for the
research study). The style of delivery is important and
we trained the facilitators to use person-centred coun-
selling techniques based on motivational interviewing
(open questioning, affirmation, reflective listening,
summaries, use of the Ask-Tell-Discuss technique for
information exchange) [31, 32] to promote autonomous
motivation and to deliver all of the intervention con-
tent. A selection of 3–4 audio recordings per facilitator
of session delivery is reviewed to check fidelity of inter-
vention delivery. Facilitators also self-complete a fidelity
checklist at the end of each session. The senior staff
use this data to a) develop training updates and b) give
the facilitators individual formative feedback. Supervi-
sion meetings are held approximately every 2 months,
where barriers and solutions to delivery are discussed.
The intervention is delivered in local community
venues (e.g. community halls, University premises etc.).
Control group(s)
Participants in the control groups (Projects 2 and 6) are
offered attendance at the first available planned session
for their chosen intervention location. This session is
offered within 4 weeks of being randomised into the
control arm of the programme. If a particpant was un-
able to attend this session the next planned session was
offered to them. The 2-h control session offers the same
education as the intervention but in condensed form.
The content relates to ‘pre-diabetes’ and T2DM risk and
weight, physical activity and dietary behaviour in relation
to T2DM risk and amangement Control participants are
asked to attend follow up appointments at 6, 12, 24, 36,
40 and 46 months and to complete questionnaires.
Process questionnaires designed to test the behaviour
change model underpinning the intervention were given
to all intervention group and half (randomly selected) of
controls. In the areas where the study took place, the
control session matched closely what is offered in pri-
mary care as a standard pathway of care, to those newly
diagnosed with a ‘prediabetes’ category (Table 1). Partici-
pants with T2DM in control and intervention groups
receive standard care through their normal GP diabetes
service in line with local primary care diabetes manage-
ment guidelines.
Process evaluation (Table 9)
Process evaluation is an integral part of the trial and
gives greater explanatory power to the outcome mea-
sures a better understanding of the mechanisms of ac-
tion, likely generalisability of the intervention, and
assesses intervention fidelity and participant adherence.
The process evaluation includes:
a) Higher level process analysis: Tests a physiological
causal model for diabetes prevention, and examines
the mediating role of changes in dietary and physical
activity behaviours on the intervention effect on
T2DM incidence. This analysis uses the T2DM
incidence, accelerometer data, and short form
IPAQ questionnaire [33] (to measure physical
activity) and the Dietary Behaviour Questionnaire
(DBQ) adapted from the original Fat and Fibre
Related Diet Behaviour Questionnaire [34] to
measure dietary behaviour change
b) Intermediate level process analysis: Examines the
mediating effect of intervention exposure on
behaviour change and other study outcomes, using
individual level measures of intervention attendance
on study outcomes. Fidelity of the intervention is
assessed in two ways. Firstly, by scoring of delivery
quality, based on a checklist completed by DPF to
provide an overall score relating to style of delivery
and content provision. The BECCI [35] and MITI
coding systems [36] are examples of this approach.
Secondly, by coding of recordings of delivered
sessions by independent raters (in a subsample).
c) Finer-grained process analysis: Tests the
underpinning theoretical model of behaviour
change, and whether the intervention leads to
changes in targeted processes such as understanding
the behaviour change process, and motivational
variables such as perceived importance and
self-efficacy, and social support. The mediating
effect of changes in process variables on changes
in dietary and physical activity behaviour and
weight are examined using the process measures
described in Table 9.
Primary outcomes
The primary end point in Project 2 is the diagnosis of
T2DM based on paired fasting plasma glucose results
both ≥7.0 mmol/l, or both HbA1c results ≥48 mmol/mol
at 46 months after enrollment. One time point result in
this range [≥7.0 mmol/l, or ≥48 mmol/mol] triggers a re-
peat fasting sample for fasting plasma glucose and
HbA1c to confirm a diagnostic end point, and a T2DM
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Table 9 Process Evaluation questionnaire measures
Process Measures [all at 0, 4, 12, 24 and 40 months]
Understanding the process of behaviour change Brief questionnaire piloted/refined with feedback from 15 people and (along with all the
newly developed/adapted measures below) validated in a separate study [66]: Covers
knowledge about how to make permanent changes to behaviour, how to get and stay
motivated, the perceived importance of social support, knowing how to overcome barriers
and having skills to manage food cravings (the key processes underpinning the NDPS
intervention model).
Explore and enhance motivation [Perceived Importance
of lifestyle change]
Perceived importance of eating a healthy diet [with a brief definition provided]: We used a
0 to 10 visual analog scale [VAS] and have also adapted the Intrinsic Motivation Inventory
[67, 68] by reducing the number of items to 4 and providing 3 specific intrinsic motivations
that should be relevant to the target group and/or which are targeted by the intervention
[helping to control my weight; reducing my risk of getting heart disease; contributing to
my sense of well-being]. Perceived importance of doing at least 150 min/week of moderate
to vigorous physical activity [MVPA]: We also used a 0 to 10 VAS and the same 4 items from
the IMI.
Explore and enhance motivation [Confidence about ability
to change]
Self-efficacy for healthy eating: we used a 5-item reduced/modified version of the Weight
Efficacy Life-Style Questionnaire [69]. We also used a 0 to 10 VAS scale to assess confidence
about eating a healthy diet [definition provided] over a] the next month and b] the next
12 months
Self-efficacy for achieving a healthy level of Physical Activity: we use a 5-item physical
activity self-efficacy scale [70]. We also used a 0 to 10 VAS scale to assess confidence
about being able to achieve a healthy level of physical activity [definition provided] over
a] the next month and b] the next 12 months.
Identify and engage sources of social support Social support for healthy diet: we used a 5-item adaptation of the Sallis et al. scale developed
by Norman et al. [71, 72] Social support for healthy level physical activity : we used a 5-item
adaptation of the Sallis scale developed by Roesch et al. [71, 73]
Intention Formation Intention for healthy diet: We developed a brief 4 item measure, using a 5-point Likert scale
to assess the level of agreement/disagreement with statements about intention to a) eat
healthily and b) adhere to the three main healthy eating recommendations of the
programme.
Intention for physical activity: We developed a 3 item measure using 2 items from
Sniehotta et al. [74] and a further item about doing moderate intensity activity on 5 days of
the week. We used the same 5-point Likert response scale as above.
Action planning Level of engagement with action planning process. 1. From coding of completed action
plans (intervention group only) to indicate level of engagement with the key elements of
goal-setting, coping planning and social support planning, as well as participant ratings of
how useful the plans/reviewing of plans were. 2. We used 4 items on action planning and
3 items on coping planning from the scale developed by Sniehotta et al. [75]
Self-Regulation (monitoring and problem-solving relating
to diet and physical activity)
Frequency of self-monitoring and relapse management activities: We used two pre-existing items
on self-monitoring [74], two newly constructed items on attempts to identify and solve problems,
and one (new) item on general salience of physical activity aims, all over the last month.
Frequency of weighing: 1 item from Linde et al. [76]
Barriers/problem-solving (intervention group only): We coded progress-review sheets and
coping plans used in the intervention under four sub-headings: Practical barriers; People
and places; Thoughts and feelings; Other. Level of engagement in this problem-solving
activity was defined in terms of the number of items recorded on the written plans in a
defined time period prior to measurement.
Empathy/empowerment Client Satisfaction (intervention group only): Items from the Learning Climate Questionnaire
[77] to assess how much empathy/empowerment and engagement participants felt they
have with the intervention facilitators.
Quality of intra-group interactions Physical Activity Group Environment Questionnaire (intervention group only): We selected
the 6 items with most face validity for this intervention [78]
Affective response/reinforcement (enjoyment of or other
positive reactions to the target lifestyle changes)
Managing impulsive processes (for unhealthy eating)
Body Image Dissatisfaction
Affective response to physical activity: we selected four items from an eight-item version of a
Physical Activity Enjoyment Scale (PACES; [68]) Items were selected to represent conceptual
diversity [several items in the original scale simply use different words for ‘enjoy’]..
Affective evaluation of eating a healthy diet: We selected two items from the Interest/
Enjoyment scale of the Intrinsic Motivation Inventory [67] asking about enjoyment of
“healthy foods” [with a definition provided] and added an item asking for level of
agreement with the statement “I have found a diet that is both healthy and enjoyable”.
We selected ten items from the 18-item version of the Three Factor Eating Questionnaire
[79] These items represent the sub-scales for ‘cognitive restraint’ [all six items] and ‘uncontrolled
eating’ [four of nine items],
Perceived Body Image: We used an existing two-items Perceived Body Image questionnaire
[79, 80].
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primary end point is only confirmed when both samples
are concordant. The primary end point in Project 4 is
HbA1c at 46 month project end as a measure of gly-
caemic control between groups with screen detected
T2DM. Power estimates and sample size are based on
biologically relevant differences in mean HbA1c between
groups at project end. The primary end point in Project
6 is HbA1c at 40 month project end as a measure of gly-
caemic control between groups.
Secondary outcomes
In Project 2, 4 and 6 there are six sets of prespecified
secondary end points in each trial with analysis between
arms for these outcomes at trial end, and at interval time
points, between groups. These are a] homeostasis model
assessment [HOMA] estimates of insulin sensitivity and
beta cell function based on fasting plasma glucose and
insulin levels [37], b] exercise levels based on accelerom-
eter data and self-reported activity and International
Physical Activity Questionnaires [IPAQ] [33], c] dietary
intake based on self-reported Diet Behaviour Questionnaire
designed in house [DBQ] d] weight, body fat mass, visceral
fat, BMI and waist circumference e] Changes in the ques-
tionnaire designed to measure health status [EQ–5D],
Well-Being Questionnaire, 12 items [WBQ-12], item 1
from the Audit of Diabetes-Dependent Quality-of-Life
questionnaire [ADDQoL], [38, 39] and study specific ques-
tionnaire data f] weighted composite lifestyle change score
based on changes in weight, BMI, waist circumference and
exercise levels. One pre specified secondary analysis in
Project 2 is to analyse the cumulative incidence of
T2DM in a composite analysis group of the two inter-
vention arms combined, compared to controls. This
will be undertaken if the primary comparison between
intervention groups in Project 2 end is not significant.
In Project 4 in addition to these secondary end points we
also collect diabetes specific questionnaire data on
Diabetes Treatment Satisfaction Questionnaire [DTSQs]
and Diabetes Management Self-Efficacy Scale [DMSES] at
each time point [40, 41]. In Project 3 the primary objective
is to recruit, train and retain volunteers with T2DM to be
DPMs. However, as secondary end points we also collect
DPM biometrics at, 0,6, 12,24 and 36 months [HbA1c,
weight, blood pressure, waist circumference, body fat mea-
surements and BMI], and at the same time points collect
changes in exercise levels [based on self-reported activity
and IPAQ questionnaire], changes in dietary intake based
on self-reported DBQ questionnaire, quality of life and
psychological well-being measured by WBQ-12, DMSES,
ADDQoL and DTSQ as individuals who provide social
support through volunteering experience less depression,
heightened self-esteem and self-efficacy, and improved
quality of life, and improved health outcomes. We also
collect data on the DPM perceptions of their capacity to
deliver the NDPS intervention measured by focus groups
and confidential views on DPM intervention efficacy in a
study specific questionnaire and focus groups. These sec-
ondary DPM data will be analysed longitudinally within
group between baseline and end point.
Sample size estimates, original and revised power
calculations
Original NDPS sample size and power estimates [2010] were
based on transition rates from IFG [>6.1–<7.0 mmol/l] to
T2DM in Northern European white populations. In the
Danish ADDITION study [42] annual transition rates
were 11.8% in 1821 individuals with IFG [mean age
60 years; mean BMI 29.1 kg/m2 and similar to our
population] with a transition rate highest in the first
year. In the Inter99 study [43], the transition rate was
10.4% for those with IFG – IGT combined in younger
and slimmer participants [age 42.7 years; BMI 27.7 kg/m2]
although 50% had already had diet and lifestyle interven-
tions. We assumed an annual incidence rate of 8% was
reasonable, at a 22% cumulative incidence over 3 years
[allowing for incident cases]. Meta- analysis of pub-
lished diabetes prevention trials at the time [44] sug-
gested an estimated effect size effect sizes based on a
meta - analysis effect size of 0.51 [95% CI 0.44–0.66] of
diet and lifestyle interventions in IGT suggesting we
could look for an equivalent effect size in our intervention
groups with a 4% annual progression in the intervention
group [12% cumulative incidence over 3 years allowing for
incident cases]. A 36 month intervention asymmetrically
randomized controlled trial of 170 controls [standard care]
and 390 intervention participants gave 80% power at 5%
significance level to detect this difference in proportion
progressing [project 2]. We hypothesized that the interven-
tion effect size would be further enhanced by additional
support from the DPM with enhanced weight loss, weight
loss maintenance and exercise adherence, which was poor
at DPP end [3]. The lowest quartile dietary fat intake par-
ticipants in the Finnish Diabetes Prevention study [45] had
half the T2DM incidence compared to highest quartile,
with an overall mean 58% reduction, and we hypothesized
that the enhanced DPM group would experience a further
reduction in the T2DM incidence rate to 2% per annum
[6% cumulative incidence over 3 years], then 390 additional
IFG participants will provide 80% power at 5% significance
level to detect this difference in proportions progressing
compared to the intervention alone.
The move to a diagnostic cut point of HbA1c ≥48
mmol/mol for diabetes [13, 14] largely supplanted diag-
nosis based on fasting glucose or oral glucose tolerance
test criteria. This policy generates a large population
with NDH HbA1c ≥42–<48 mmol/mol iand UK policy
guidance [15] is that these patients should receive
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intensive lifestyle advice and annual HbA1c monitoring.
This change occurred during the early accrual period of
NDPS (largely based on glucose entry criteria at incep-
tion) and we adapted the programme to take this into
account as the HbA1c defined population is likely to be-
come the dominant ‘pre diabetes’ population in UK
practice in the next few years. Meta - analysis of predia-
betes transition rates [46] suggest that this HbA1c de-
fined NDH population have an annualised T2DM
incidence of 4.7% [95% CI 3.7–5.9] for a glucose based
T2DM end point, independent of any concurrent fast-
ing glucose classification. In earlier meta analyses, an-
nual progression rate to T2DM based on a NDH,
independent of any concurrent fasting plasma glucose
data, was 5–10% per annum, with an estimated annual-
ised transition to T2DM of 7.5% at a mean HbA1c of
approximately 44 mmol/mol [47]. In NDPS, mean
HbA1c in the NDH group was 43.7 [SD 1.4] mmol/mol
for the earlier screened population [Project 1]. Lipska
et al. [48], demonstrated that the combination of both
NDH range HbA1c and IFG was associated with a rela-
tive risk of T2DM of 26.2 [95% CI 16.3–42.1] compared
to those with neither, with a transition rate to T2DM of
7% per annum in the combined group. Similar risk sig-
nals at this level are apparent in other populations for a
combined lower range IFG (>5.6–<6.1 mmol/l) and
NDH with transition rates approaching 10% per
annum, at an age and gender adjusted hazard ratio of
38.6 [95% CI 27.6–54.0] compared to normal glycaemic
status [47, 48]. Because of this policy change [13–15]
and these data, since 2014 we have also randomized
participants into Project 2 if they had an HbA1c ≥42 to
<48 mmol/moll combined with an elevated fasting
plasma glucose ≥5. 6–<6.1 mmol/l Current revised
power estimates reviewed and approved by independent
DMEC, TSC, sponsor and funding body are based on a
final accrued sample size of 972 in Project 2, with a
46 month follow up and end of trial 1.4.18. Current re-
tention and follow up data, and above assumed transi-
tion rates as above, gives 99.7% power to detect these
difference between controls and intervention, 84%
power between controls and intervention plus DPM
arm, and 78.6–80.2% power to detect a difference
between the two intervention arms. In Project 4 in
order to have 80% power to detect a difference of 0.5%
in HbA1c between groups at end of trial, (0.4 standard
deviations based on screen detected HbA1c distribu-
tion) requires 99 participants per group, and to allow
for a drop-out rate of 20%, a total of 375 individuals
will be randomised. The transition rate to T2DM for
subjects with NDH and a normal fasting glucose
(<5.6 mmol/l) is not clear, and Project 6 is not powered
to detect differences in transition rates to T2DM, but is
an observational RCT in this understudied group.
Statistical analysis plan
For project 2 we will use an intention-to-treat approach.
For binary outcomes we will use the chi-squared test or
logistic regression if adjustment for baseline imbalances
is required; for continuous outcomes we will use the t-test
for comparison of two arms or analysis of covariance for
comparison of all three. For time-to-event outcomes the
proportional hazards model will be used with time mea-
sured from randomisation until the end of the study or
drop-out [censoring] or diabetes is diagnosed. Secondary
analyses will include a per-protocol analysis and analysis
of secondary outcome measures. For determinants of pro-
gression we will use logistic regression and the proportion
hazards model with the time of the onset of T2DM as the
outcome measure in each treatment arm separately as well
as compliance with the intervention. If necessary we will
use multiple imputation to assess sensitivity to missing
data. For project 2, the primary outcome measure is pro-
gression to T2DM by study exit. This will be analysed
using a logistic regression model including a covariate to
account for the different potential follow-up times at base-
line. A secondary analysis will adjust for potential prog-
nostic factors which will be agreed prior the final analysis.
Secondary continuous outcome measures will be analysed
using a general linear model in a similar fashion using the
study exit. Time-until progression to T2DM will be ana-
lysed using a discrete time survival analysis model. A lon-
gitudinal analysis of the continuous secondary endpoints
will also be undertaken to assess for differences over time
using a random effect approach. Effect sizes will be esti-
mated for all two-way comparison of intervention group
and no adjustment for multiple testing will be undertaken.
The primary analyses will be based on the intention-to-
treat population but, if appropriate, a CACE analysis will
also be undertaken for the primary outcome. Adverse
events will be tabulate but no formal comparison will be
undertaken. A similar approach will applied to Project 4
with HbA1c as the primary outcome between groups with
T2DM. In Project 6 a similar approach will be applied
with HbA1c as the primary outcome between groups.
Recruitment strategies
Methods: assignment of intervention and allocation
Randomisation of participants is conducted using a dedi-
cated function in the trial data management system. The
randomisation mechanism consists of a pre-prepared
random list of codes [for the Intervention and Control
groups] that are stored in a table in the trial database.
To reduce the risk of predicting the next allocation while
maintaining a reasonable even spread of intervention
and control patients, the list is constructed of blocks of
17 codes 3 control, 7 intervention and 7 intervention +
DPM to approximate the proportions of 170:390:390
respectively.
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The list were built prior to the start of the programme
using standard Microsoft tools. Randomisation is asym-
metric to deliver sample sizes described. Projects 4 and
6 are randomised using the same method in the trial
data mangement system. Project 4 are randomised to a
1:1:1 ratio and the Project 6 is randomised to a 1:1 ratio
to control or intervention only.
Methods: data management
All study data are recorded and stored on the study
database [CRF/eCRF]. Each clinic appointment has a
dedicated paper CRF designed for optimal collection of
data in line with study protocol compliance and regula-
tory requirements. CRF’s are prepared in line with proto-
col development and version controlled. All clinical
measurements are recorded on both the CRF and the
eCRF simultaenously at the time of the clinic appoint-
ment. Data entry and daily data management is per-
formed via the dedicated secure database website. The
NDPS Data Management Plan describes the intended
procedures for managing data in the NDPS. An updated
report of missing/erroneous data is generated weekly to
aid data cleansing in real time. Each participant has a
data cleansing section on their database page which re-
cords all data checking activity. Questionnaire entry is
monitored weekly via the NDPS update report, gener-
ated directly from the database. This allows weekly mon-
itoring of registration, overall accrual for each project,
accrual by site, withdrawal rates, the rate of registration
versus consent to screening, and adherence to interven-
tion sessions.
Methods: biochemical analyses
Fasting plasma glucose [hexokinase/G-6-PDH method
Architect c8000: Abbott Diagnostics, Maidenhead, UK],
HbA1c [Affinity high performance liquid chromatog-
raphy; Hb9210: Menarini Diagnostics Ltd., Wokingham,
RG41 5RA, UK], Total Cholesterol: enzymatic: cholesterol
oxidase/hydrogen peroxide, Triglyceride: Enzymatic: gly-
cerol kinase/hydrogen peroxide, HDL cholesterol : Direct
method using a specific detergent to solubilise HDL Chol-
esterol/cholesterol esterase; LDL cholesterol - Calculation
using the Friedewald formula:LDL-C (mmol/L) = Total
CHOL (mmol/L) - (HDL-C (mmol/l) + TRIG (mmol/l)
Insulin - solid-phase, enzyme-labelled chemiluminescent
sandwich immunometric assay (Siemens Healthcare Diag-
nostics, Camberley, GU16 8QD).
Ethics and dissemination
Ethics approval
NHS Research Ethics Committee [REC] - NRES Com-
mittee East of England Essex reviewed applications for
research and gave a favourable ethical opinion for
proposed participant involvement on the 3th January
2011 [REC number 10/H0301/55]. To date 40 substan-
tial protocol amendments, and 38 minor amendments
have been made to the programme along with 2 sub-
missions for a Site Specific Information [SSI] to allow
two further NHS secondary care trusts to conduct the
research at their particular locality All significant
protocol amendments have been REC reviewed and
approved, and approved by host organisation and
NIHR programme board. In line with Ethical approval
for this programme, participants can withdraw from
the programme at any point, without having to give
reasons for withdrawal. Participants who do decide to
withdraw are given the option to withdraw completely
from all further contact, or to agreed to further con-
tact for time point blood sampling for biochemical
end points and diagnosis as per protocol, but without
intervention. Participants reaching a prespecified end
point of new T2DM diagnosis leave the programme
and are managed by normal primary care services.
Consent, security, and confidentiality
Participants are provided with the patient information
sheet [PIS] for all NDPS trials prior to registration or at
the time of registration. At registration verbal consent is
obtained from each participant prior to recording details
on the study database [eCRF]. The study is fully ex-
plained by a member of the team at registration and the
partcipant is given the opportunity to ask questions
prior to written informed consent being taken at the first
screening clinic appointment. Written informed consent
is taken from participants prior to both screening proce-
dures being undertaken and prior to randomisation into
any group. The multiple PIS and consent forms are sum-
marised in the Additional files 1, 2, 3, 4 and 5. Data is
stored in a secure database on the Clinical Trials Unit
[CTU] Microsoft’s SQL Server system at the University
of East Anglia. Access to the server is restricted abso-
lutely to CTU data management staff and NDPS staff
working on the programme. User access is authorized by
the PI or CI and the database is protected by usernames
and passwords. The server and its contents are covered
by the UEA IT regulations and policies. Data on the ser-
ver is backed up nightly and regularly archived to off-
site storage. In addition, other ‘quick-access’ backups are
taken by the NDPS Database Manager and held on-line
to facilitate rapid recovery of recently changed data.
Each user has an individual username and password
without which they are able to access the system and
any attempt to access pages ‘deeper’ into the NDPS data
entry system will automatically be re-routed to the login
page. Traffic between the user’s PC and the server is
secured using standard SSL [Secure Sockets Layer] tech-
nology. Unattended PCs left logged onto the system are
Pascale et al. BMC Public Health  (2017) 17:31 Page 16 of 21
‘timeout’ after a period. All identifiable data is stored in
locked cabinets in authorised card entry offices or
clinics. Access to the final trial dataset will be limited to
CI, PI and programme statistician.
Methods: monitoring
The NDPS has a dedicated independent Data Monitor-
ing and Ethics Committee [DMEC]. The committee
reviews accumulating data and advises the Chief and
Principal Investigator directly and indirectly via the
programme statistician, on the future management of
the trial. The committee reviews the safety, efficacy,
quality and compliance data of the programme at yearly
committee meeting and bi-monthly reports. The DMEC
is privy via a closed session with the core statistical
team, to interim comparisons by arm and may deter-
mine the form of data analysis, end point adjudication
and interim analyses to be undertaken. The DMEC re-
port is presented to the Trial Steering Committee [TSC]
which meets 6 monthly. The DMEC and TSC terms of
reference and membership are available. The study is
fully GCP compliant and is audited by the host
organization Research and Innovation Department. The
programme receives formal quality assurance support
from the Norwich CTU including the documentation of
all quality procedures in a Quality Management Plan
and assistance to set up the TSC and DMEC with roles
and responsibilities of these committees documented in
line with established guidelines.
Protocol amendments
All protocol amendments have been made in accordance
with the Research Ethics Committees [REC] standard
operating policies. All amendments have been submitted
for REC, Research Health Authority [RHA], sponsor Re-
search & Innovation Department approval prior to
implementing. All significant amendments to protocol
have been reviewed by funding body [NIHR PGfAR]. All
amendments have been documented in a protocol
amendment tracker [see Additional file 3]. The initial
protocol was approved by REC in January 2011, and
current protocol is version 13]. Protocols v2 - v4, v7, v9,
v10, and v12 were for minor textual changes in mate-
rials. v5 allowed new geographical areas to be accessed
to maintain accrual, v6, v8 and v9 recorded additional
supplementary studies, including epigenetic analysis
[V6], iron balance studies [v9], and Project 6 to take into
account new categories of NDH [v8]. v11 [3.4.14] was a
larger scale amendment that allowed access to new pop-
ulations in Suffolk and Essex to maintain power, to pro-
long follow up to 46 months and revised inclusion
criteria for randomisation into Project 2 that recognised
the recent development of new diagnostic criteria for
diabetes and NDH based on HbA1c criteria.
Ancillary and post - trial care
Participants with screen detected T2DM randomised to
Project 4 also receive standard best practice diabetes
care through their general practice. The programme
does not interfere with any element of their normal
diabetes care. All participants have access to a DPF,
the Principal Investigator or Chief Investigator if they
wish to discuss their diagnosis and implications of
these results. However, in all cases the participants are
encouraged to discuss their diagnosis/results with
their GP. Post - trial (April 2018) all participants in
this programme will be maintained in primary care
follow up in line with normal clinical best practice at
that time (2018). All participants and GPs will be writ-
ten to with a data summary, diagnostic categorisation,
and suggested further follow and care plans.
Dissemination
The main NDPS trial(s) will be submitted for publication
in July 2018. All participants and participating GPs will
be sent a summary of trial outcomes, linked to current
models of care and diabetes prevention strategies at the
time.
Economic evaluation
We will estimate the cost-effectiveness of the Norfolk
DPS intervention [with and without DPM], compared to
the control arm, for individuals identified as having IFG
or T2DM. The level of resource use associated with the
intervention [including that associated with the educa-
tion and maintenance sessions, as well as DPM input]
will be estimated along with other NHS resources that
are potentially related to the intervention [e.g. referrals
to dietician and GP visits]. Appropriate unit costs e.g.
[49] will be assigned to all resource items. The economic
evaluation will use the EQ-5D [50] as the main measure
of effectiveness, enabling QALY [quality adjusted life
year] scores to be estimated. Costs and QALYs incurred
in future years will be discounted. Subsequently, the in-
cremental cost-effectiveness ratio will be calculated and
compared to a range of cost-effectiveness thresholds
[51]. In order to characterise the level of uncertainty the
cost-effectiveness acceptability curve [52] will also be
presented. Sensitivity analysis will also be undertaken to
assess the robustness of conclusions to key assumptions
that are made within the economics analysisIf there are
differences in T2DM incidence or in cardiovascular risk
factors at the end of project 2, the ongoing effects,
health care costs and cost effectiveness of the interven-
tion will be modelled over the projected lifetimes of par-
ticipants. Risks of complications of T2DM will be based
primarily on the UKPDS risk engine [53, 54], risks of
coronary heart disease and stroke will be based primarily
on QRISK2-2016 [55]. NHS costs of T2DM, cardiovascular
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risk factors and diabetes complications will be based on
published estimates. Residual death rates will be based on
UK Office of National Statistics estimates. This will be a
multistate life table model, in which, for each surviving per-
son each year, values of risk factors, adverse outcomes will
be simulated, based on the values in the preceding year and
assumed annual changes in risk factors and on incidence of
adverse outcomes. The quality of life of each individual
each year will be calculated, based on the presence of ad-
verse outcomes, using primary quality of life data from pro-
ject 2, and published estimates of QALYs associate with the
respective outcomes. Simulation of the cohort will end
when 99% have been simulated to die. As with the within-
trial economic evaluation, incremental cost effectiveness ra-
tios will be estimated and cost effectiveness acceptability
curves will be presented. A probabilistic sensitivity analysis
will be conducted, incorporating parameter and stochastic
uncertainty. Other sensitivity analyses will explore the sen-
sitivity of the primary analysis to assumptions about key
parameters such as risks of T2DM, coronary heart disease,
stroke, death, quality of life, costs and discount rates.
Discussion
The need for effective diabetes prevention strategies to
be developed at scale in existing health care systems was
recognised by the announcement of the NHS England
diabetes prevention programme in 2015 [9, 56]. This
national programme was largely predicated on existing
evidence of diabetes prevention benefit in very large
well - resourced clinical trials [3–5] in highest risk indi-
viduals. There is a substantial translational literature,
examining the more variable impact of shorter term
and less intense lifestyle interventions on glycaemic and
metabolic outcomes in high risk groups [6–8]. Recent
meta - analysis [8] of 44 clinical studies (8995 partici-
pants) has shown that modified, simpler and shorter in-
terventions based on the US diabetes prevention
programme (DPP), and using different delivery models,
is associated with significant weight loss and reductions
in HbA1c, but the diabetes prevention impact of these
models remains uncertain. There is also still uncer-
tainty over the best approach to find those at highest
risk of T2DM for a clinical or research intervention,
and over which glycaemic category should receive the
intervention [6]. It seems sensible to develop and test
research interventions that would be translatable to
normal clinical practice, that recognises the complex-
ities of risk categorization, and the need to reduce
intervention costs. The NDPS will address many of
these issues and reports in 2018.
The arguments underlying the NDPS programme
(2011–2018) are similar to those used later in the NHS
England prevention programme (2015), that the costs of
research based diabetes prevention interventions are
prohibitive, that new approaches are needed to deliver
the intervention (based on group work), potentially
using lay mentors to deliver the intervention and recog-
nizing the need to limit impact on pressured primary
care teams. The value of the NDPS programme has in-
creased since inception, as it will answer many of the
current questions about delivery of the NHS England
programme [9, 56], and also provide crucial trial out-
comes trial data for the high risk group with non - dia-
betic hyperglycaemia (NDH). The trial evidence in this
population is relatively limited [8, 9, 56] and the shift in
diagnostic criteria for diabetes [13–15] from glucose
based to HbA1c based diagnostic criteria has created
large populations with NDH. There are also limited data
on the diabetes prevention intervention benefit in the
population with IFG, based on a fasting plasma glucose
test, rather than impaired glucose tolerance based on a
time consuming (for patients and staff ) oral glucose
tolerance test, which would not be widely used for mass
population screening for those at high risk in a non - re-
search active primary care setting [16, 17]. These at risk
glycaemic categories (based on HbA1c and fasting
plasma glucose) have been for some time the largest at
risk glycaemic populations identified in UK general prac-
tice. The NDPS programme recognises the complexity
of the these various categories of ‘prediabetes’, and
randomizes clinicallt recognizable combinations combi-
nations of these categories into trial(s) and will provide
evidence for progression and risk reduction in these
categories.
One important element of NDPS is that screening pro-
grams or case finding in general practice for people at
highest risk with IFG, IGT or NDH will also generate
significant populations with screen detected T2DM. In
NDPS we randomize these participants into the same
intervention groups (Project 4). This trial will answer
the question of whether a diabetes prevention interven-
tion also has glycaemic outcomes benefit in people with
screen detected T2DM, and replicates normal clinical
practice.
Peer support can be defined as support from persons
who have the same health condition as the people they
assist and who experience similar challenges of those
with the condition [10–12]. The use of lay mentors or
community health care workers to support a lifestyle
intervention, and reduce the very high costs of more
intensive research interventions was recognized by the
early triallists [3]. Evaluation of the role of lay supporters
generally report positive participant perceptions and
biomedical outcomes [10–12]. Although the role is vari-
ously described most of the diabetes literature has exam-
ined impact on the clinical care of people living with
diabetes [10–12] and the higher the intensity of the pro-
gram the greater the reduction in HbA1c [12]. The use
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of unpaid volunteers with T2DM themselves to provide
peer support in the context of T2DM prevention trial is
a novel approach [57]. This model offers real
opportunities to devlop a new volunteer workforce with
T2DM who have a shared interest in diet, lifestyle and
glycaemic outcomes to the participants they are support-
ing in a diabetes prevention intervention In NDPS, the
diabetes prevention mentors deliver support by tele-
phone, and telephone communication has been found to
be acceptable by patients and is commonly a preferred
and convenient option [58, 59].
The screening element of NDPS [project 1] uses existing
GP practice databases to identify those at highest risk for
further screening, with minimal impact on GP workload,
using standard and very simple database queries in the
commonest UK database systems, where search terms are
available for almost all patients. This deliberate approach
was developed to limit workload within practices and
encourage practice engagement without using model-
ling from more complex risk prediction tools where
data on predictive variables may be unavailable [18, 60, 61].
The data from the screening element of this programme
will have value in itself, as it will allow estimates of the
population size of the various glycaemic categories in
normal GP practice databases. The simple search cri-
teria used in NDPS were also chosen to ensure NDPS
was concordant with the 2010 NHS national vascular
screening programme [62, 63]. This mass primary care
cardiovascular risk screening programme in England
uses age >40 year and BMI >30 kg/m2 as criteria for
further fasting plasma glucose or HbA1c testing, is
now a mandatory requirement for local authorities in
England [63].
The NDPS programme is projected to reach full sample
size and power on current accrual rates and will report in
mid – 2018 for all trials.
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